Pakistan Pharmaceuticals: Profitability continued to rise led by positives – By JS Research
Oct 7 2025
JS Global Capital
- We analyze 2QCY25 performance of the listed pharmaceutical sector, using a sample size of 9 companies. Our sample posted 11% YoY increase in net revenue to Rs79bn, mainly attributable to the deregulated non-essential drug prices. Likewise, gross margin improved to 41%, up 7ppts YoY during the period mainly led by higher pricing, lower API prices, and stable currency.
- On QoQ basis, our sample companies’ sales remained flat owing to the seasonality impact, however, gross margins improved by 2ppts to 41% during the outgoing quarter.
- During FY25, the sample posted a revenue growth of 16% YoY, arriving at Rs314bn during the year. Wherein, the earnings improved by 2.6x YoY led by positives as discussed above.